Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RYZ-101 by RayzeBio for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
RYZ-101 is under clinical development by RayzeBio and currently in Phase III for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData,...